

Role of Soluble Transferrin Receptor in diagnosing Iron Deficiency Anemia in maintenance hemodialysis patients

Thesis

Submitted for partial fulfillment of Master Degree
in Internal Medicine

By

Marwa Eid Abdulhady Naker

M.B.B.CH.

Under Supervision of

Prof. Dr. Khaled Hussein Abou Seif

Professor of Internal Medicine and Nephrology
Faculty of Medicine - Ain Shams University

Assist. Prof. Hussein Sayed Hussein

Assistant Professor of Internal medicine and Nephrology
Faculty of Medicine - Ain Shams University

Dr. Shaimaa Zaki Abdelmegied

Lecturer of Internal medicine and Nephrology
Faculty of Medicine - Ain Shams University

**Faculty of Medicine
Ain Shams University
2020**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سَبِّحْناكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢



Acknowledgments

*First and foremost, I feel always indebted to **Allah**, the **Most Beneficent** and **Merciful**, Who gave me the strength to accomplish this work,*

*My deepest gratitude to **Prof. Dr. Khaled Hussein Abou Seif**, Professor of Internal Medicine and Nephrology, Faculty of Medicine - Ain Shams University, for his valuable guidance and expert supervision, in addition to his great deal of support and encouragement. I really have the honor to complete this work under his supervision.*

*I would like to express my great and deep appreciation and thanks to **Assist. Prof. Hussein Sayed Hussein**, Assistant Professor of Internal Medicine and Nephrology, Faculty of Medicine - Ain Shams University, for his meticulous supervision, and his patience in reviewing and correcting this work,*

*I can't forget to thank with all appreciation **Dr. Shaimaa Zaki Abdelmegied**, Lecturer of Internal medicine and Nephrology, Faculty of Medicine - Ain Shams University, for the efforts and time she has devoted to accomplish this work,*

*Special thanks to my **Parents**, my **Husband** and all my **Family** members for their continuous encouragement, enduring me and standing by me.*

 **Marwa Eid Abdulhady Naker**

List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations.....	i
List of Tables.....	iii
List of Figures	v
Introduction	1
Aim of the Work.....	4
Review of Literature	
Anemia in hemodialysis patients	5
Soluble transferrin receptors	31
Diagnosis of iron deficiency anemia in hemodialysis patients	44
Patients and methods	57
Results.....	65
Discussion	84
Summary	90
Conclusion.....	93
References	94
Appendix	I
Arabic Summary	—

List of Abbreviation

ACD	Anemia of chronic disease
ACEI	Angiotensin Converting Enzyme Inhibitor
ARBs	Angiotensin receptor blockers
AVF	Arterio-venous fistula
CHR	Content of Hb in reticulocytes
CKD	Chronic kidney disease
CLL	Chronic lymphocytic leukemia
CRP	C-reactive protein
ELISA	Enzyme linked immunosorbent assay
EMPs	Erythropiotein mimetic peptides
EPO	Erythropiotein
ESA	Erythropioesis stimulating agents
ESRD	End stage renal disease
Hb	Hemoglobin
HIF1	Hypoxia inducible factor 1
HIF-PHIs	Hypoxia-inducible factor prolyl hydroxylase inhibitors
HIF-PHD	Hypoxia-inducible factor Prolyl hydroxylase
ID	Iron deficiency
IDA	Iron deficiency anemia
IL1	Interleukin 1
IL6	Interleukin 6
IRMA	Immuno-radiometric assay
IV	Intravenous
KDIGO	Kidney disease improving global outcome
KDOQI	Kidney disease outcome quality initiative
MCH	Mean corpuscular hemoglobin
MCHC	Mean corpuscular hemoglobin concentration

MCV	Mean corpuscular volume
MDS	Myelodysplastic diseases
NO	Nitric oxide
NPP	Negative predictive value
PPV	Positive predictive value
PTH	Parathyroid hormone
RBCs	Red blood cells
ROS	Reactive oxygen species
STFRs	Soluble transferrin receptors
TFR	Transferrin receptor
TFR-F	Transferrin receptor - ferritin index
TGF B	Transforming growth factor B
TIBC	Total iron binding capacity
TNF	Tumor necrosis factor
TSAT	Transferrin saturation
WBCs	White blood cells
ZnPP\H	Zinc protoporphyrin/heme
ZPP	Zinc protoporphyrin

List of Tables

Table No.	Title	Page No.
Table (1):	Plasma Half-Lives of Erythropoietin Analogues.....	19
Table (2):	Causes of hypo-responsiveness to ESA:.....	23
Table (3):	New Erythropoietic Strategies.....	25
Table (4):	Comparison between group A and group B as regard age, sex and smoking:.....	66
Table (5):	Comparison between group A and group B as regard the cause of ESRD	67
Table (6):	Comparison between group A and group B as regard comorbidity:.....	68
Table (7):	Comparison between group A and group B as regard duration of hemodialysis, ESA therapy and dialysis prescription	69
Table (8):	Comparison between group A and group B as regard parametric laboratory data.	70
Table (9):	Comparison between group A and group B as regard non parametric laboratory data...	71
Table (10):	Demographic & laboratory data of the control group:.....	72
Table (11):	ROC curve of STFRs in prediction of iron deficiency anemia	73
Table (12):	Comparison between hemodialysis patients and control as regard STFRs prevalence	74

Table (13):	Prevalence of STFRs in group A and group B.....	74
Table (14):	Comparison between group A and group B as regard classic markers of iron deficiency anemia (iron profile) and STFRs.....	76
Table (15):	Comparison between the control group, group A and group B as regard hemoglobin, MCV, MCH and STFRs	77
Table (16):	Logistic regression analysis for predictors of STFRs and Hb between Control subject and Group A.....	79
Table (17):	Logistic regression analysis for predictors of STFRs and Hb between Control group and Group B	80
Table (18):	Correlation between STFRs to all variable in group A and group B	81
Table (19):	Correlation between STFRs to all variable in the control group	83

List of Figures

Figure No.	Title	Page No.
Figure (1):	Schema to demonstrate peritubular fibroblast-like type-1 interstitial cells.....	7
Figure (2):	The EPO endocrine feedback loop	8
Figure (3):	Cellular basis of erythropoietin deficiency in renal failure	11
Figure (4):	In renal anemia, the kidney's ability to produce EPO is impaired	15
Figure (5):	Target hemoglobin (Hb) concentration during erythropoiesis -stimulating agent treatment	21
Figure (6):	HIF activity under normoxic/hypoxic conditions and HIF-PHI inhibition, and its effects on erythropoiesis	26
Figure (7):	Schematic of the TfR molecule showing the change leading to sTfR	34
Figure (8):	Roles of current and newly proposed markers of iron status.....	51
Figure (9):	Comparison between group A and group B as regard CRP.	71
Figure (10):	The roc curve of STFRs for prediction of iron deficiency anemia.....	73
Figure (11):	Comparison between group A and group B as regard prevalence of STFRs.	75
Figure (12):	Comparison between group A and group B as regard STFRs.....	76

Figure (13): Comparison between the control group, group A and group B as regard Hb.....	78
Figure (14): Comparison between the control group, group A and group B as regard STFRS.....	78
Figure (15): Negative correlation between STFRs and KT\V in group A.....	82
Figure (16): Negative correlation between STFRs and s.iron in group A.	82

Abstract

Background: Diagnosis of iron deficiency is traditionally based on ferritin and other iron parameters becomes difficult in end stage renal disease patients due to the inflammatory condition which affects these markers and masks the iron deficiency. Serum soluble transferrin receptor (sTfR) is able to be a reliable indicator for assessing iron status, as it is not affected by inflammatory procedures.

Aim: To evaluate the usefulness of serum soluble transferrin receptors in iron deficiency anemia detection in comparison to the classic markers of iron status in prevalent hemodialysis patients.

Methods: This case-control study assessed sTfR in 80 prevalent ESRD patients on regular hemodialysis in 2 groups. Group A (N=40): CRP >10 and group B (N=40): CRP <10 and apparently healthy 8 control subjects.

Results: The cut of value of STFRs in hemodialysis patients was 12.5 mg/l. The prevalence of STFRs in patients with CRP<10 was 85%, while in patients with CRP>10 was 92.5% (P-value 0.288). STFRs have high sensitivity 88.75, specificity 100, PPV100% and NPV 47.1%. The hemodialysis patients who have elevated STFRs have risk 1.22 times to have iron deficiency anemia if CRP <10 (odds ratio: 1.22) and 3.14 times if CRP>10 (odds ratio: 3.14). There was significant difference on comparing patients with CRP<10, CRP>10 and control as regard Hb and STFR with P-value 0.0001 and 0.0001 respectively.

Conclusion: Serum soluble transferrin receptor is highly sensitive and specific marker for iron deficiency in hemodialysis patients especially in patients with high CRP level.

Key-words: soluble transferrin receptors, iron deficiency anemia, hemodialysis.

Introduction

Anemia is a common finding in hemodialysis patients. There are numerous factors that relate renal dysfunction to anemia such as:

- 1- Accumulation of uremic toxins that act as apoptosis inducers in erythroid precursors in bone marrow.
- 2- Raised quantities of free radicals and reactive oxygen species (ROS) – for instance nitric oxide (NO) and superoxide anions – synthesized by activated macrophages, affecting erythroid precursors
- 3- Blood loss related to hemodialysis procedure and gastrointestinal hemorrhage
- 4- Dilutional anemia due to disturbance of kidney filtration and excessive retention of fluids (**Banerjee, 2009**).

Reduced production of erythropoietin synthesized by endothelial cells of the capillaries surrounding kidney tubules during the course of renal complication, is another contributing factor to anemia (**Lodish H.; et al., 2010**).

Erythropoietin therapy – nowadays administered as recombinant human erythropoietin – is one of the main approaches to correct anemia in hemodialysis patients. One of the most important reasons of unresponsiveness to this treatment is shortage of body iron supply. Therefore, a precise assessment of iron storage in hemodialysis patients is of vital

value to identify patients with actual iron deficiency and adjust treatment accordingly (**Tomczak-Watras *et al.*, 2009**)

The gold standard for identification of iron deficiency induced anemia is iron stain on liver or bone marrow biopsy samples (**Wulfhekel *et al.*, 1999**).

This is a precise approach, yet an invasive one, and in case of existence of any replacement it is better avoided. One alternative approach is evaluation of two red blood cell indices – mean corpuscular volume (MCV) and mean corpuscular hemoglobin concentration (MCHC) and detection of microcytic and hypochromic red blood cells as confirmation of existence of iron deficiency. Nevertheless, these two parameters are affected by the existing inflammation (**Koulaouzidis *et al.*, 2009**)

Serum ferritin and transferrin saturation (TSAT) are two most commonly done tests used for evaluating iron deficiency anemia. However, these tests do not consistently reflect the iron status of patients with CKD on hemodialysis (**Saboor *et al.*, 2011**)

Serum ferritin and transferrin are considerably influenced by acute phase responses in inflammation. Total iron binding capacity (TIBC) is a negative acute phase reactant. Moreover, TSAT fluctuates because of diurnal variation in serum iron

levels. In recent years, soluble transferrin receptor (sTfR) has been introduced as a sensitive, early and valuable new marker of iron depletion (**Majeed et al., 2016**)

STfR is a truncated form of the transferrin receptor present on erythroblasts in bone marrow and many other cells. As sTfR concentration is not usually affected by inflammation or infection but in conditions where iron deficiency co-exists with anemia of chronic disease, sTfR raises secondary to underlying iron deficiency (**Latif et al., 2017**).

Aim of the work

The aim of this study is to evaluate the usefulness of serum soluble transferrin receptors in iron deficiency anemia detection in comparison to the classic markers of iron status in prevalent hemodialysis patients.